Paul Evans, PhD, President and Chief Executive Officer of Velocity, has been named a featured speaker of the Biotech and Pharmaceutical Management Summit through Cornell University. The summit at Cornell Tech will enable participants to engage with industry leaders and Cornell faculty in small panel discussions on topics such as the payer perspective, barriers and … Read more
Wiesbaden is the second largest city in the Frankfurt Rhine Main region of Germany, with a population of more than 300,000 people. The city is known for its architecture and is one of the oldest spa towns in Europe, with 26 hot springs. It is also home to Velocity’s latest site acquisition. Velocity acquired InterMed … Read more
Velocity Clinical Research (“Velocity”), the leading multi-specialty clinical site organization, today announces it has made three C-suite hires, as the company continues to dramatically expand its clinical site and patient organization, bringing research opportunities to more people. Nick Campbell joins as Chief Commercial Officer, Nick Spittal is the company’s new Chief Operating Officer, and Steph … Read more
To gain deeper insight into the perspectives of clinical trial participants, Velocity has built the Participant Advisory Committee (PAC). The PAC comprises diverse current and past clinical trial participants from across the country. The Velocity PAC convenes regularly to discuss issues and share ideas that could improve the clinical research process now and for future … Read more
Tyler Adam, MD, Principal Investigator at Velocity Clinical Research in Hastings, NE, supported the promising MATISSE Phase 3 maternal RSV vaccine study — results of which have been published in the article, “Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants” in the New England Journal of Medicine. In this global trial, … Read more
Neuroscience company Cognivue enrolled more than double the national average participation rate of diverse populations in its Further the Objective and Clinical Understanding of Cognivue Study (FOCUS) study. Velocity supported the study by enrolling the entirety of the study’s more than 1,500 subjects across 14 sites and 11 states. While typical studies of this size … Read more
Velocity Clinical Research is now a Society for Clinical Research Sites (SCRS) Global Impact Partnership (GIP). Paul Evans, PhD, President and CEO of Velocity, said the company is excited to leverage this partnership to further improve clinical research, both within Velocity and industry-wide. “The SCRS community can play an integral role in the way sites … Read more
Clinical trials — especially high-volume trials — are primarily designed to collect quantitative data. Collecting and reviewing qualitative data and experiential feedback from trial participants is rarely prioritized. Before being acquired by Velocity Clinical Research, Meridian Clinical Research built an in-house surveying system to elevate the participant’s voice. The system, which is largely automated, collects … Read more
Velocity Clinical Research (“Velocity”), the largest integrated research site organisation globally, today announces it has strengthened its European senior executive team with three strategic hires, as the firm continues its expansion in the region. Évelyne Newton joins as Vice President of Business Development, Sandra Stark is Vice President of European Operations and Maria Lehretz is … Read more
1: Consolidation and scale of the market It is well known that fragmentation of the clinical sites business has been identified as a market opportunity by private equity firms. As a result of a PE capital injection, there has been increased merger and acquisition activity within the sector, leading to a level of consolidation that … Read more